KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Alnylam Pharmaceuticals (ALNY) Assets Average (2016 - 2025)

Alnylam Pharmaceuticals' Assets Average history spans 16 years, with the latest figure at $4.9 billion for Q4 2025.

  • For Q4 2025, Assets Average rose 16.26% year-over-year to $4.9 billion; the TTM value through Dec 2025 reached $4.9 billion, up 16.26%, while the annual FY2025 figure was $4.6 billion, 14.08% up from the prior year.
  • Assets Average reached $4.9 billion in Q4 2025 per ALNY's latest filing, up from $4.7 billion in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $4.9 billion in Q4 2025 to a low of $3.3 billion in Q1 2021.
  • Average Assets Average over 5 years is $3.8 billion, with a median of $3.6 billion recorded in 2021.
  • Peak YoY movement for Assets Average: skyrocketed 42.52% in 2021, then decreased 1.96% in 2023.
  • A 5-year view of Assets Average shows it stood at $3.6 billion in 2021, then decreased by 0.48% to $3.5 billion in 2022, then increased by 8.29% to $3.8 billion in 2023, then grew by 10.12% to $4.2 billion in 2024, then rose by 16.26% to $4.9 billion in 2025.
  • Per Business Quant, the three most recent readings for ALNY's Assets Average are $4.9 billion (Q4 2025), $4.7 billion (Q3 2025), and $4.4 billion (Q2 2025).